EPIGENETIC THERAPY FOR FRIEDREICH’S ATAXIA: A PHASE 1, FIRST IN MAN, ASCENDING DOSE CROSSOVER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RG2833 (A HISTONE DEACETYLASE INHIBITOR) IN ADULTS WITH FRIEDREICH’S ATAXIA
Networked Digital Library of Theses and Dissertations